Table 1.

Discussion of knowledge gaps/key recommendations for future research

Opening remarks - Emily Erbelding, M.D. and Xin-Xing Gu, M.D.

SESSION 1. Vaccine platforms, technology, targets to improve and/or replace aP vaccines – Moderated by Kathryn M. Edwards, M.D.

• Overview of pertussis - Kathryn M. Edwards, M.D.

• Pertussis Epidemiology and Vaccination: A United States Perspective - Anna M. Acosta, M.D.

• Pertussis immunity, acellular vaccines and model-based inference: modeling effectiveness and durability of vaccination - Pej Rohani, Ph.D.

SESSION 2. Basic Research Strategies – Moderated by Eric Harvill, Ph.D.

• Improving Protective Immunity by Manipulating Bacterial Immuno-modulators - Eric Harvill, Ph.D.

• Durable Vaccine Immunity: Challenges and Potential Solutions - Purnima Dubey, Ph.D.

• Correlates of Immunity and Immunological Memory - Kingston Mills, Ph.D.

SESSION 3. Translational Research Strategies – Moderated by Kathryn M. Edwards, M.D. and Eric Harvill, Ph.D.

• Impact of Waning Immunity on Evolving Pertussis Epidemiology - Nicola Klein, M.D., Ph.D.

• Landscape of Novel Vaccine Targets - F. Heath Damron, Ph.D.

• Innovative Pertussis Vaccine Technology Platforms - Peter Sebo, Ph.D.

SESSION 4. Clinical Research Strategies

• Age-specific TLR7/8 adjuvant formulation overcomes hyporesponsiveness to neonatal acellular pertussis vaccination in a mouse model - Jay Evans, Ph.D.

• Better Memory Through TCF1 - Ross M. Kedl, Ph.D.

• Adjuvant Effects of Monophosphoryl Lipid A - Thomas C. Mitchell, Ph.D.

• Predictive in vitro Immunological Assays - Marcela F. Pacetti, Ph.D.

• Baboon Model of Pertussis: Predictive pre-clinical animal models - Tod J. Merkel, Ph.D.

• Bordetella pertussis Human Challenge Induces Immunizing, Asymptomatic Colonization - Robert C. Read, M.D.